Adimab Provides Year-End Update on 2024 Partnership Activities

0
Adimab Provides Year-End Update on 2024 Partnership Activities

– 17 New Partnerships –

– 51 Milestones Achieved in 2024 –

– Over 600 Total Therapeutic Programs at Year-End –

LEBANON, N.H., January 13, 2025–(BUSINESS WIRE)–Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, today announced that it entered into partnership agreements with 17 new companies in 2024. In addition, Adimab announced the expansion of eight of its current partnerships and the achievement of 51 technical and development milestones across numerous collaborations.

Adimab has partnered with over 130 companies to discover therapeutic programs, to date. New alliances for 2024 include collaborations with Candid Therapeutics, Champlain Bio, GV.M1, Helicore Biopharma, Incendia Therapeutics, Inc., Leyden Labs, Remunix, Sedare Biosciences, Inc., Stipple Bio, Meiji Seika Pharma and Treeline Biosciences, among others. In addition, Adimab expanded its collaborations with eight partners, including Alnylam, Cullinan Therapeutics, GSK, iOmx, Novartis, Santa Ana Bio, and Werewolf.

In 2024, Adimab and its partners initiated discovery on 62 new therapeutic programs, bringing the total number of royalty-bearing programs commenced to over 600. Many partners retain the contractual rights to initiate additional royalty-bearing programs with Adimab in the future.

“Adimab’s platform stands out in the field of protein-based therapeutic discovery due to our unique ability to leverage a highly proprietary eukaryotic discovery system and a vast human antibody library in an IgG format, yielding exceptional specificity and developability in our output,” said Guy Van Meter, Chief Business Officer of Adimab. “Across more than 600 therapeutic programs to date, no project has ever been discontinued for developability issues, which is an achievement unmatched by any other technology in the field. This reflects the unparalleled robustness and reliability of our platform.”

“Our competitive edge extends beyond technology; it lies in the unmatched experience of our team. At Adimab, we foster a culture where every employee is motivated by the success of our partners, which has allowed us to attract and retain some of the best talent in the industry. With the wisdom gained from hundreds and hundreds of therapeutic programs, we bring a level of expertise that ensures success in every new project. This is another reason why Adimab stands as the most successful antibody technology company in the industry — enabling our partners to bring better therapeutic programs to patients,” said Philip T. Chase, Chief Executive Officer of Adimab.

link

Leave a Reply

Your email address will not be published. Required fields are marked *